Abstract 5239
Background
ALK inhibitors (ALKi) have shown substantial benefit in pts with advanced ALK+ NSCLC. We describe real-world treatment patterns and outcomes in pts with ALK+ advanced NSCLC in the US.
Methods
This retrospective cohort study utilised US electronic health record data from Flatiron Health. Pts diagnosed with stage IIIB-IV ALK+ NSCLC from 1 Jan 2011 to 30 Sep 2018 were included. Treatment patterns and outcomes (real-world progression-free survival [rwPFS] and overall survival [OS]) were extracted for first- or second-line therapy. Time to treatment discontinuation (TTTD) was used as a surrogate for real-world treatment duration accounting for treatment beyond progression. Time-to-event analyses were performed using Kaplan-Meier methods.
Results
Data were available for 620 pts with ALK+ advanced NSCLC. An ALKi was given to 420/620 (67.7%) pts as first-line therapy and 273/359 (76.0%) pts who received second-line therapy. Among non-ALKi treatments, platinum-based regimens were the most common. Crizotinib was the preferred first-line ALKi up to 2016, and then alectinib. As second-line therapy, crizotinib was the preferred ALKi up to 2013, followed by ceritinib from 2014–2015, and then alectinib to the end of the follow-up period. TTTD, rwPFS and OS were longest with alectinib, followed by crizotinib and non-ALKi (Table).Table:
1546P
1L | Outcome | Statistics | Alectinib (n = 98) | Ceritinib (n = 4) | Crizotinib (n = 318) | non-ALKi (n = 200) |
---|---|---|---|---|---|---|
rwPFS | Median (95% CI), months | NR | 5.06 (0.72, NR) | 6.41 (5.92, 8.16) | 8.26 (6.25, 9.9) | |
6-month probability (95% CI) | 0.83 (0.75, 0.91) | 0.5 (0.19, 1) | 0.55 (0.49, 0.6) | 0.59 (0.52, 0.66) | ||
12-month probability (95% CI) | 0.68 (0.58, 0.79) | 0.25 (0.05, 1) | 0.32 (0.27, 0.38) | 0.37 (0.3, 0.44) | ||
TTTD | Median (95% CI), months | NR | 6.1 (0.72, NR) | 7.57 (6.97, 9.14) | 3.12 (2.76, 4.38) | |
6-month probability (95% CI) | 0.85 (0.78, 0.92) | 0.5 (0.19, 1) | 0.61 (0.56, 0.67) | 0.35 (0.29, 0.43) | ||
12-month probability (95% CI) | 0.73 (0.64, 0.84) | 0.25 (0.05, 1) | 0.36 (0.31, 0.42) | 0.21 (0.16, 0.28) | ||
OS | Median (95% CI), months | NR | 6.1 (0.72, NR) | 23.06 (16.51, 30.86) | 27.99 (21.6, 36.51) | |
6-month probability (95% CI) | 0.92 (0.87, 0.98) | 0.5 (0.19, 1) | 0.78 (0.73, 0.82) | 0.84 (0.79, 0.89) | ||
12-month probability (95% CI) | 0.85 (0.77, 0.93) | 0.25 (0.05, 1) | 0.65 (0.6, 0.7) | 0.71 (0.65, 0.78) | ||
2L | Outcome | Statistics | Alectinib (n = 90) | Ceritinib (n = 75) | Crizotinib (n = 97) | non-ALKi (n = 86) |
rwPFS | Median (95% CI), months | 13.59 (10.33, NR) | 6.32 (4.64, 8.45) | 6.88 (4.9, 9.87) | 4.4 (2.96, 6.81) | |
6-month probability (95% CI) | 0.76 (0.68, 0.86) | 0.51 (0.4, 0.64) | 0.54 (0.45, 0.65) | 0.4 (0.31, 0.52) | ||
12-month probability (95% CI) | 0.55 (0.44, 0.68) | 0.25 (0.16, 0.37) | 0.35 (0.26, 0.46) | 0.22 (0.14, 0.33) | ||
TTTD | Median (95% CI), months | 19.84 (14.54, NR) | 8.19 (6.22, 11.84) | 8.72 (7.37, 5.36) | 4.61 (3.42, 6.18) | |
6-month probability (95% CI) | 0.85 (0.77, 0.93) | 0.61 (0.5, 0.73) | 0.66 (0.57, 0.76) | 0.39 (0.3, 0.51) | ||
12-month probability (95% CI) | 0.68 (0.58, 0.8) | 0.34 (0.24, 0.47) | 0.41 (0.32, 0.52) | 0.18 (0.11, 0.28) | ||
OS | Median (95% CI), months | NR | 16.84 (9.51, 33.75) | 22.3 (17.17, 45.23) | 15.56 (11.41, 26.94) | |
6-month probability (95% CI) | 0.92 (0.86, 0.98) | 0.75 (0.65, 0.86) | 0.85 (0.78, 0.93) | 0.71 (0.62, 0.82) | ||
12-month probability (95% CI) | 0.85 (0.77, 0.93) | 0.59 (0.48, 0.71) | 0.69 (0.6, 0.79) | 0.56 (0.46, 0.68) |
1L, first-line therapy; 2L, second-line therapy; ALKi, ALK inhibitor; rwPFS, real-world progression-free survival; TTTD, time to treatment discontinuation; OS, overall survival; NR, not reached (median survival estimate could not be calculated).
Conclusions
The use of ALKi in the US reflects current clinical guidelines. Despite the choice and established benefit of individual ALKi as first-line therapy, more than 25% of pts received a non-ALKi as first-line therapy, even in recent years (2017/2018). Furthermore, in clinical practice, treatment beyond progression with an ALKi is relatively common. OS for non-ALKi was comparable to some ALKi, but OS is also reflective of treatment received in later lines of therapy.
Clinical trial identification
Editorial acknowledgement
Nicola Griffin of Gardiner-Caldwell Communications, funded by F. Hoffmann-La Roche.
Legal entity responsible for the study
F. Hoffmann-La Roche Ltd.
Funding
F. Hoffmann-La Roche Ltd.
Disclosure
M.G. Krebs: Advisory / Consultancy: Achilles Therapeutics, Janssen, Octmet and Roche; Research grant / Funding (self): BerGenBio and Roche; Travel / Accommodation / Expenses: AstraZeneca and BerGenBio; Research grant / Funding (institution): AstraZeneca, Bayer, BerGenBio, Blueprint, Carrick, Immutep, Incyte, Janssen, Merck, Octimet and Roche. L. Polito: Full / Part-time employment: F. Hoffmann-La Roche Ltd. V. Smoljanović: Full / Part-time employment: F. Hoffmann-La Roche Ltd. H. Trinh: Full / Part-time employment: Genentech Inc. G. Crane: Full / Part-time employment: Genentech Inc.
Resources from the same session
2182 - Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Presenter: Keiichi Ota
Session: Poster Display session 1
Resources:
Abstract
5255 - [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma
Presenter: Liang Zhao
Session: Poster Display session 1
Resources:
Abstract
4910 - Expression of PD-L1 in Chinese Patients with Common Cancers
Presenter: Min Zheng
Session: Poster Display session 1
Resources:
Abstract
4227 - The clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin
Presenter: Irina Larionova
Session: Poster Display session 1
Resources:
Abstract
5222 - VHIO-300 and a thousand one nights, a tale of Precision Medicine
Presenter: Ginevra Caratù
Session: Poster Display session 1
Resources:
Abstract
5668 - Matched Whole-Genome Sequencing and Whole-Exome Sequencing with Circulating Tumor DNA (ctDNA) Analysis are complementary modalities in clinical practice
Presenter: Robin Imperial
Session: Poster Display session 1
Resources:
Abstract
5772 - Exploring the role of genes associated with familial cancer syndromes on the development of multiple primary tumors
Presenter: Atanaska Mitkova
Session: Poster Display session 1
Resources:
Abstract
4784 - Doxorubicin resistance: early and advanced tumors can use two different strategies based on initial and profound abnormalities in microRNA expression signature
Presenter: Volodymyr Halytskiy
Session: Poster Display session 1
Resources:
Abstract
3456 - From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments
Presenter: Yuna Blum
Session: Poster Display session 1
Resources:
Abstract
4976 - Optimization of automated germline DNA extraction from non-tumoral formalin-fixed paraffin embedded (FFPE) tissues
Presenter: Omar Youssef
Session: Poster Display session 1
Resources:
Abstract